A user gained 10-12 kg after starting finasteride but found their estrogen levels to be within the normal range. They are concerned about potential gynecomastia but are reassured by their lab results.
A 35-year-old transitioning female (MtF) shared her hair regrowth journey using Minoxidil, Dutasteride, Microneedling, and Exosomes, starting from a bald state. Commenters discussed the impressive results, skin care routine, and the effects of estrogen on hair and skin.
Men with early male pattern baldness (MPB) may have hormonal abnormalities similar to those in women with PCOS. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The user has androgenetic alopecia (AGA) and low Vitamin D levels, and they started using topical minoxidil (5%). They are considering finasteride but are concerned about side effects and are advised to seek mental health support.
The user experienced hair improvement using a topical finasteride, minoxidil, and tretinoin combo, along with supplements like zinc, copper, magnesium, vitamin D3, K2, iodine, and boron. They believe these changes are due to addressing mineral deficiencies and possibly thyroid issues, despite skepticism from others.
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
A 16-year-old girl is experiencing hair loss, which has worsened despite using minoxidil and multivitamins. Suggestions include broader hormone testing and considering other treatments like spironolactone if the hair loss is due to androgenic alopecia.
A user's claim that they have reversed their hair loss with the treatments Dutasteride RU58841, Minoxidil and castration; however, other users are skeptical of this claim.
The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.
A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.
The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.
The conversation is about a person starting treatment with RU58841 for hair loss. They are asked to share progress pictures to show if the treatment is effective.
A user shared their hair transformation over four months using daily 2.5mg oral minoxidil, every other day 1mg oral finasteride, weekly dermastamping, and daily scalp massages, with plans for a hair transplant. Another user suggested continuing the medication for a year before considering a transplant.
The user had a hair transplant in 2021 with 1600 grafts and is currently using finasteride, minoxidil, biotin, and collagen. They are considering another transplant in Turkey to address a bald spot and improve coverage in the front and middle.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
A 39-year-old man shared his 18-month hair regrowth progress using oral dutasteride, oral minoxidil, saw palmetto, biotin, red light therapy, and microneedling. He experienced significant improvement after switching from finasteride to dutasteride and adding oral minoxidil, with plans to possibly consider a hair transplant in the future.
The user has been on finasteride for 18 months and added dutasteride after the first 6 months, with no hair regrowth observed. Bloodwork shows normal levels of DHT despite the use of both medications.
The user discussed switching from RU58841 with Minoxidil to Finasteride due to cost, noting better physical feelings and hair growth with RU58841. They are considering returning to RU58841 and checking DHT levels after a month.
A 19-year-old is distressed about his 17-year-old autistic brother's hair loss, projecting his own insecurities despite being on finasteride and dutasteride. Replies suggest the brother might not care about balding, and the poster should address his own issues.
The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.
An 18-year-old experienced initial hair improvement with minoxidil but noticed increased shedding after surgery and lifestyle changes. They suspect iron deficiency and are seeking other possible explanations for the hair loss.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.
The user experienced significant hair regrowth using KX-826 (pyrilutamide) 0.9% over one year, despite initial shedding phases. They reported no side effects and have stabilized hair loss with consistent use.
The user's hair appears to have improved, looking thicker and healthier, especially around the temples, after using topical minoxidil, finasteride, dutasteride, and tretinoin. Most participants agree the last picture shows significant improvement, though one disagrees.
An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.